Kymera Therapeutics, Inc.
KYMR
$82.21
-$2.29-2.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -12.58% | -16.70% | -50.05% | -49.51% | -25.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.58% | -16.70% | -50.05% | -49.51% | -25.85% |
| Cost of Revenue | 23.11% | 31.77% | 37.56% | 39.10% | 38.85% |
| Gross Profit | -32.99% | -43.58% | -94.88% | -104.18% | -83.04% |
| SG&A Expenses | 10.46% | 7.32% | 10.02% | 9.33% | 15.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.66% | 26.65% | 31.58% | 32.46% | 33.50% |
| Operating Income | -27.69% | -34.61% | -68.18% | -72.63% | -60.72% |
| Income Before Tax | -30.77% | -39.08% | -76.22% | -74.49% | -55.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.77% | -39.08% | -76.22% | -74.49% | -55.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.77% | -39.08% | -76.22% | -74.49% | -55.82% |
| EBIT | -27.69% | -34.61% | -68.18% | -72.63% | -60.72% |
| EBITDA | -28.31% | -35.13% | -69.80% | -72.70% | -60.43% |
| EPS Basic | -15.21% | -24.00% | -54.48% | -44.10% | -23.89% |
| Normalized Basic EPS | -13.79% | -25.46% | -57.29% | -48.38% | -27.43% |
| EPS Diluted | -15.21% | -24.00% | -54.48% | -44.10% | -23.89% |
| Normalized Diluted EPS | -13.79% | -25.46% | -57.29% | -48.38% | -27.43% |
| Average Basic Shares Outstanding | 14.83% | 12.62% | 17.74% | 21.45% | 25.72% |
| Average Diluted Shares Outstanding | 14.83% | 12.62% | 17.74% | 21.45% | 25.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |